<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626067</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #06-762E</org_study_id>
    <secondary_id>CMS-06-09</secondary_id>
    <nct_id>NCT00626067</nct_id>
  </id_info>
  <brief_title>Study of Patient Use and Perception of the Travatan Dosing Aid</brief_title>
  <official_title>Pilot Study of Patient Acceptance and Impact of the New Travatan™ Compliance Monitoring Dispenser (Travatan™ Dosing Aid)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the opinions of patients who are given&#xD;
      the Travatan Compliance Monitoring Dispenser to use to dispense their Travatan glaucoma&#xD;
      drops.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients enrolled in this study will use the new Travatan compliance monitoring dispenser for&#xD;
      6 weeks. Patients will be informed that some, but not all, patients' compliance will be&#xD;
      monitored by the device. Patients are randomly assigned to one of three groups&#xD;
      (proportionally in a 2/2/1 ratio):&#xD;
&#xD;
        1. Fully functional Travatan compliance monitor&#xD;
&#xD;
        2. Travatan compliance monitor with LCD display and alarms disabled, but compliance&#xD;
           monitoring intact&#xD;
&#xD;
        3. Travatan compliance monitor with LCD display, alarms and compliance monitor disabled.&#xD;
&#xD;
      At end of study, patients fill out questionnaire assessing&#xD;
&#xD;
        1. Patient opinion regarding device: ease of use of new device; preference vs Travatan use&#xD;
           without device, etc&#xD;
&#xD;
        2. patient's belief as to whether their compliance was monitored or not&#xD;
&#xD;
      Rates of adherence are compared across groups and with regard to patients' reported beliefs&#xD;
      as to whether they were monitored.&#xD;
&#xD;
      The design of this study should allow the clinicians to ethically monitor compliance in&#xD;
      patients who do and do not believe that they are being monitored. The use of monitoring&#xD;
      devices without a functioning display and alarm should lead to some patients believing that&#xD;
      they are not being monitored. As patients are told at the outset that they may or may not be&#xD;
      monitored, this should be an ethically acceptable design. However, the collected data will&#xD;
      allow a preliminary assessment of the impact of the patients' beliefs as to whether they are&#xD;
      being monitored on their actual compliance, and hence an additional potential value of the&#xD;
      device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess patients' opinions regarding new Travatan Compliance Monitoring Dispenser</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pilot study of the impact of physician monitoring of compliance on patient compliance</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>1 Fully functional monitoring device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fully functional monitoring device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Partially functional monitoring device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Partially functional monitoring device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Non-functional monitoring device</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Non-functional monitoring device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fully functional monitoring device</intervention_name>
    <description>Pt received fully functional monitoring dispenser for use with their Travatan eye drops</description>
    <arm_group_label>1 Fully functional monitoring device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Partially functional monitoring device</intervention_name>
    <description>Patient received a particually functional Travatan Compliance Monitoring Dispenser</description>
    <arm_group_label>2 Partially functional monitoring device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-functional monitoring device</intervention_name>
    <description>Patient received a non functioning Travatan Compliance Monitoring Dispenser</description>
    <arm_group_label>3 Non-functional monitoring device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Open angle glaucoma or ocular hypertension&#xD;
&#xD;
          -  Presently using Travatan eye drops&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to prostaglandin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan S. Myers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Institute</affiliation>
  </overall_official>
  <link>
    <url>https://doi.org/10.2147/PPA.S114746</url>
    <description>Patient Preference and Adherence</description>
  </link>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>January 22, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Jonathon Myers</investigator_full_name>
    <investigator_title>Attending Surgeon</investigator_title>
  </responsible_party>
  <keyword>Travatan Dosing Aid</keyword>
  <keyword>compliance monitoring dispenser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A Manuscript has been accepted and published in Patient Preference and Adherence.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

